<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1812-9528</journal-id>
<journal-title><![CDATA[Memorias del Instituto de Investigaciones en Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Mem. Inst. Investig. Cienc. Salud]]></abbrev-journal-title>
<issn>1812-9528</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Investigaciones en Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1812-95282025000100210</article-id>
<article-id pub-id-type="doi">10.18004/mem.iics/1812-9528/2025.e23122510</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Bioequivalencia in vitro de psicoterapéuticos adquiridos por el Estado peruano: caso, Carbamazepina y Diazepam]]></article-title>
<article-title xml:lang="en"><![CDATA[In vitro bioequivalence of psychotherapeutics acquired by the Peruvian state: case, Carbamazepine and Diazepam]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ganoza-Gasco]]></surname>
<given-names><![CDATA[Frizzi J.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alva-Plasencia]]></surname>
<given-names><![CDATA[Pedro M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Saldaña-Bobadilla]]></surname>
<given-names><![CDATA[Vanessa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gutiérrez-Ramos]]></surname>
<given-names><![CDATA[Miriam]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ayala-Jara]]></surname>
<given-names><![CDATA[Carmen]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Velasquez-Arevalo]]></surname>
<given-names><![CDATA[Sharon]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gomes-Ferraz]]></surname>
<given-names><![CDATA[Humberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Trujillo Facultad de Farmacia y Bioquímica Departamento de Farmacotécnia]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Perú</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de São Paulo Facultad de Ciencias Farmacéuticas ]]></institution>
<addr-line><![CDATA[São Paulo ]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Trujillo Facultad de Farmacia y Bioquímica Departamento de Bioquímica]]></institution>
<addr-line><![CDATA[Trujillo ]]></addr-line>
<country>Perú</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>23</volume>
<numero>1</numero>
<fpage>210</fpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1812-95282025000100210&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1812-95282025000100210&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1812-95282025000100210&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La evaluación de la bioequivalencia desempeña un papel fundamental en la determinación de la calidad y eficacia de los medicamentos genéricos. En el caso específico de los psicofármacos, como la carbamazepina (CBZ) y el diazepam (DZP), la equivalencia biofarmacéutica a nivel in vitro es prioritaria. Estos medicamentos se emplean ampliamente en el manejo de diversas afecciones neurológicas y psiquiátricas. El objetivo fue determinar la bioequivalencia in vitro de carbamazepina y diazepam adquiridos por el Estado peruano. Se realizó control de calidad, validación del método y determinación de los perfiles de disolución comparados con el medicamento innovador, mediante el factor de similitud (f&#8322;). Se encontraron diferencias significativas en los controles de calidad, el método fue validado con éxito y además existen más diferencias significativas en el perfil de disolución de carbamazepina que en diazepam. La bioequivalencia in vitro con el innovador solo fue demostrada por el lote multifuente de diazepam adquirido por EsSalud.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Bioequivalence assessment plays a fundamental role in determining the quality and efficacy of generic drugs. In the specific case of psychotropic drugs, such as carbamazepine (CBZ) and diazepam (DZP), their in vitro biopharmaceutical equivalence is a priority. The objective was to determine the in vitro bioequivalence of carbamazepine and diazepam purchased by the Peruvian government. Quality control, method validation, and determination of dissolution profiles compared to the innovator drug were performed using the similarity factor (f&#8322;). Significant differences were found in quality controls; the method was successfully validated; and there are more significant differences in the dissolution profile of carbamazepine than diazepam. In vitro bioequivalence with the innovator was only demonstrated by the multisource batch of diazepam acquired by EsSalud.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Biodisponibilidad]]></kwd>
<kwd lng="es"><![CDATA[bioexención]]></kwd>
<kwd lng="es"><![CDATA[perfil de disolución]]></kwd>
<kwd lng="es"><![CDATA[validación]]></kwd>
<kwd lng="en"><![CDATA[Bioavailability]]></kwd>
<kwd lng="en"><![CDATA[biowaiver]]></kwd>
<kwd lng="en"><![CDATA[dissolution profile]]></kwd>
<kwd lng="en"><![CDATA[validation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[WHO Expert Committee on Specifications for Pharmaceutical Preparations: Forty-second report]]></source>
<year>2008</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Lennernäs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Crison]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>1995</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>413-20</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davit]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Nwakama]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Buehler]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2009</year>
<volume>43</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1583-97</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud, MINSA</collab>
<source><![CDATA[Decreto Supremo N° 024-2018-SA que Aprueba el Reglamento que regula la intercambiabilidad de medicamentos]]></source>
<year>2018</year>
<publisher-name><![CDATA[El Peruano]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<collab>Organización Panamericana de la Salud, OPS</collab>
<source><![CDATA[Evaluación del desempeño de los sistemas de salud: Un marco para el análisis de políticas]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Washington ]]></publisher-loc>
<publisher-name><![CDATA[PAHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<collab>British Pharmacopoeia Commission</collab>
<source><![CDATA[British Pharmacopoeia]]></source>
<year>2023</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[The Stationery Office]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<collab>US Pharmacopeia (USP)</collab>
<source><![CDATA[USP 43/NF 38. The United States Pharmacopeial Convention]]></source>
<year>2020</year>
<publisher-loc><![CDATA[Baltimore ]]></publisher-loc>
<publisher-name><![CDATA[United Book Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>Cytiva</collab>
<source><![CDATA[Quantitative ashless filter paper. Lab filtration products - Cellulose filter papers]]></source>
<year>2025</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Fifty-first report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>U.S. Department of Health and Human Services, FDA, CDER</collab>
<source><![CDATA[Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a BCS Guidance for Industry]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Evaluación de los perfiles de disolución de carbamazepina en tabletas de liberación inmediata de tres productos comercializados en Guatemala]]></source>
<year>2005</year>
<publisher-name><![CDATA[Universidad del Valle de Guatemala]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pringels]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Vervaet]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Verbeeck]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Foreman]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Remon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The addition of calcium ions to starch/Carbopol® mixtures enhances the nasal bioavailability of insulin]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2008</year>
<volume>68</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>201-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Der Merwe]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Steenekamp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Steyn]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hamman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2020</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>393</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Narro]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Características Fisicoquímicas De Tabletas De Diazepam 10 mg Adquiridas Por El Estado Peruano]]></source>
<year>2020</year>
<publisher-name><![CDATA[Universidad Nacional de Trujillo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[List of Essential Medicines]]></source>
<year>2019</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bermejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meulman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Davanço]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In Vivo Predictive Dissolution (IPD) for Carbamazepine Formulations]]></article-title>
<source><![CDATA[Pharmaceutics]]></source>
<year>2020</year>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>558</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sangnim]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zandu]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Development and Evaluation of MCC-SiO2/CMC-SiO2 Conjugates as Tablet Super-Disintegrants]]></article-title>
<source><![CDATA[Polymers]]></source>
<year>2022</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1035</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios</collab>
<source><![CDATA[Ficha Técnica Tegretol 200 mg comprimidos]]></source>
<year>2025</year>
<publisher-name><![CDATA[AEMPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fortunato]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dissolution Method Development for Immediate Release Solid Oral Dosage Forms]]></article-title>
<source><![CDATA[Dissolution Technol]]></source>
<year>2005</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>12-4</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salehi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kuminek]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Gousous]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers]]></article-title>
<source><![CDATA[Mol Pharm]]></source>
<year>2021</year>
<volume>18</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3326-41</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[JRD]]></given-names>
</name>
<name>
<surname><![CDATA[Lemes]]></surname>
<given-names><![CDATA[EDO]]></given-names>
</name>
<name>
<surname><![CDATA[Vargem]]></surname>
<given-names><![CDATA[DDS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influência dos excipientes na dissolução in vitro dos fármacos a partir de cápsulas gelatinosas duras contendo cetoprofeno 50 mg]]></article-title>
<source><![CDATA[Rev Eletrônica Farmácia]]></source>
<year>2016</year>
<volume>13</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>176</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Correa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Salas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Milán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Romano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Romano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacocinética poblacional de carbamazepina en niños epilépticos]]></article-title>
<source><![CDATA[Revista Mexicana de Ciencias Farmacéuticas]]></source>
<year>2009</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johannessen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Johannessen Landmark]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antiepileptic Drug Interactions - Principles and Clinical Implications]]></article-title>
<source><![CDATA[Curr Neuropharmacol]]></source>
<year>2010</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>254-67</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dávila]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cinética y perfiles de disolución de especialidades farmacéuticas de marca y de fuentes múltiples conteniendo Carbamazepina]]></article-title>
<source><![CDATA[Vérit J]]></source>
<year>2006</year>
<volume>10</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Ficha Técnica Valium 10 mg comprimidos]]></source>
<year>2025</year>
<publisher-name><![CDATA[AEMPS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Sheskey]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Quinn]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<source><![CDATA[Handbook of Pharmaceutical Excipients]]></source>
<year>2009</year>
<edition>6° edition</edition>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[Pharmaceutical Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saavedra-Suárez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alva-Plasencia]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez-Ramos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio comparativo de la calidad biofarmacéutica de Diazepam 10 mg comercializados en el mercado peruano]]></article-title>
<source><![CDATA[Ars Pharm]]></source>
<year>2022</year>
<volume>63</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-55</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alva]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lecca]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparación de perfiles de disolución de Diazepam en tabletas genéricas 10 mg y el producto innovador]]></source>
<year>2009</year>
<publisher-name><![CDATA[Universidad Nacional de Trujillo]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Novel bioequivalence approach for narrow therapeutic index drugs]]></article-title>
<source><![CDATA[Clin Pharmacol Ther]]></source>
<year>2015</year>
<volume>97</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>286-91</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindenberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dressman]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification of orally administered drugs on the WHO Model list of Essential Medicines according to the biopharmaceutics classification system]]></article-title>
<source><![CDATA[Eur J Pharm Biopharm]]></source>
<year>2004</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>265-78</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
